Appropriate dose of regorafenib based on body weight of colorectal cancer patients: A retrospective cohort study
Số trang: 9
Loại file: pdf
Dung lượng: 1.23 MB
Lượt xem: 33
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Previous randomized studies have shown a survival benefit of using regorafenib but a high rate of adverse events in unresectable colorectal cancer patients. To reduce these adverse events and improve the tolerability, we examined the appropriate dose of regorafenib based on body weight.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Reduced dose Colorectal cancer Cohort study Drug therapyGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
Ebook Canine and feline dermatology drug handbook: Part 2
225 trang 51 0 0 -
Ebook Canine and feline dermatology drug handbook: Part 1
236 trang 47 0 0 -
9 trang 43 0 0